- Previous Close
30.45 - Open
30.15 - Bid 29.40 x 28900
- Ask 29.65 x 36300
- Day's Range
29.30 - 30.50 - 52 Week Range
29.30 - 45.95 - Volume
35,237 - Avg. Volume
27,722 - Market Cap (intraday)
1.621B - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
12.38 - EPS (TTM)
2.39 - Earnings Date Apr 25, 2025
- Forward Dividend & Yield 1.89 (6.20%)
- Ex-Dividend Date Mar 21, 2025
- 1y Target Est
62.00
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
www.bbbiotech.ch/en/bb-biotech/Recent News: BBZA.DE
View MorePerformance Overview: BBZA.DE
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BBZA.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BBZA.DE
View MoreValuation Measures
Market Cap
1.66B
Enterprise Value
--
Trailing P/E
12.71
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.09
Price/Book (mrq)
0.72
Enterprise Value/Revenue
14.08
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
67.99%
Return on Assets (ttm)
1.99%
Return on Equity (ttm)
3.29%
Revenue (ttm)
111.63M
Net Income Avi to Common (ttm)
75.9M
Diluted EPS (ttm)
2.39
Balance Sheet and Cash Flow
Total Cash (mrq)
2.41B
Total Debt/Equity (mrq)
5.14%
Levered Free Cash Flow (ttm)
43.55M